Centrum Onkologii Ziemii Lubelskiej

Lublin 20-090

0 studies enrolling now · 2 studies all time

What they study most

Multiple Myeloma, NSCLC

Studies at this site

• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide — Running, not enrolling
• A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. — Stopped early